Literature DB >> 23376950

T-helper-1-cell cytokines drive cancer into senescence.

Heidi Braumüller1, Thomas Wieder, Ellen Brenner, Sonja Aßmann, Matthias Hahn, Mohammed Alkhaled, Karin Schilbach, Frank Essmann, Manfred Kneilling, Christoph Griessinger, Felicia Ranta, Susanne Ullrich, Ralph Mocikat, Kilian Braungart, Tarun Mehra, Birgit Fehrenbacher, Julia Berdel, Heike Niessner, Friedegund Meier, Maries van den Broek, Hans-Ulrich Häring, Rupert Handgretinger, Leticia Quintanilla-Martinez, Falko Fend, Marina Pesic, Jürgen Bauer, Lars Zender, Martin Schaller, Klaus Schulze-Osthoff, Martin Röcken.   

Abstract

Cancer control by adaptive immunity involves a number of defined death and clearance mechanisms. However, efficient inhibition of exponential cancer growth by T cells and interferon-γ (IFN-γ) requires additional undefined mechanisms that arrest cancer cell proliferation. Here we show that the combined action of the T-helper-1-cell cytokines IFN-γ and tumour necrosis factor (TNF) directly induces permanent growth arrest in cancers. To safely separate senescence induced by tumour immunity from oncogene-induced senescence, we used a mouse model in which the Simian virus 40 large T antigen (Tag) expressed under the control of the rat insulin promoter creates tumours by attenuating p53- and Rb-mediated cell cycle control. When combined, IFN-γ and TNF drive Tag-expressing cancers into senescence by inducing permanent growth arrest in G1/G0, activation of p16INK4a (also known as CDKN2A), and downstream Rb hypophosphorylation at serine 795. This cytokine-induced senescence strictly requires STAT1 and TNFR1 (also known as TNFRSF1A) signalling in addition to p16INK4a. In vivo, Tag-specific T-helper 1 cells permanently arrest Tag-expressing cancers by inducing IFN-γ- and TNFR1-dependent senescence. Conversely, Tnfr1(-/-)Tag-expressing cancers resist cytokine-induced senescence and grow aggressively, even in TNFR1-expressing hosts. Finally, as IFN-γ and TNF induce senescence in numerous murine and human cancers, this may be a general mechanism for arresting cancer progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23376950     DOI: 10.1038/nature11824

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  43 in total

1.  Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses.

Authors:  Ralph Mocikat; Heidi Braumüller; Alain Gumy; Oliver Egeter; Heike Ziegler; Uwe Reusch; Anja Bubeck; Jacques Louis; Reinhard Mailhammer; Gert Riethmüller; Ulrich Koszinowski; Martin Röcken
Journal:  Immunity       Date:  2003-10       Impact factor: 31.745

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Transgenic Polyoma middle-T mice model premalignant mammary disease.

Authors:  J E Maglione; D Moghanaki; L J Young; C K Manner; L G Ellies; S O Joseph; B Nicholson; R D Cardiff; C L MacLeod
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

Review 4.  Pro-senescence therapy for cancer treatment.

Authors:  Caterina Nardella; John G Clohessy; Andrea Alimonti; Pier Paolo Pandolfi
Journal:  Nat Rev Cancer       Date:  2011-06-24       Impact factor: 60.716

5.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

6.  Pancreatic β-cells activate a JunB/ATF3-dependent survival pathway during inflammation.

Authors:  E N Gurzov; J Barthson; I Marhfour; F Ortis; N Naamane; M Igoillo-Esteve; C Gysemans; C Mathieu; S Kitajima; P Marchetti; T F Ørntoft; L Bakiri; E F Wagner; D L Eizirik
Journal:  Oncogene       Date:  2011-08-15       Impact factor: 9.867

7.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

8.  IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Authors:  Bin Zhang; Theodore Karrison; Donald A Rowley; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen.

Authors:  I Förster; R Hirose; J M Arbeit; B E Clausen; D Hanahan
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

10.  Decreased tumor surveillance in perforin-deficient mice.

Authors:  M E van den Broek; D Kägi; F Ossendorp; R Toes; S Vamvakas; W K Lutz; C J Melief; R M Zinkernagel; H Hengartner
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

View more
  272 in total

1.  Structural Refinement of the Tubulin Ligand (+)-Discodermolide to Attenuate Chemotherapy-Mediated Senescence.

Authors:  Boying Guo; Alicia Rodriguez-Gabin; Andrea E Prota; Tobias Mühlethaler; Nan Zhang; Kenny Ye; Michel O Steinmetz; Susan Band Horwitz; Amos B Smith; Hayley M McDaid
Journal:  Mol Pharmacol       Date:  2020-06-26       Impact factor: 4.436

2.  Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells.

Authors:  Luke S Manlove; Katherine E Berquam-Vrieze; Kristen E Pauken; Richard T Williams; Marc K Jenkins; Michael A Farrar
Journal:  J Immunol       Date:  2015-09-16       Impact factor: 5.422

3.  Sodium channel γENaC mediates IL-17 synergized high salt induced inflammatory stress in breast cancer cells.

Authors:  Suneetha Amara; Michael T Ivy; Elbert L Myles; Venkataswarup Tiriveedhi
Journal:  Cell Immunol       Date:  2015-12-19       Impact factor: 4.868

Review 4.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

5.  Coadministration of a Plasmid Encoding HIV-1 Gag Enhances the Efficacy of Cancer DNA Vaccines.

Authors:  Laure Lambricht; Kevin Vanvarenberg; Ans De Beuckelaer; Lien Van Hoecke; Johan Grooten; Bernard Ucakar; Pascale Lipnik; Niek N Sanders; Stefan Lienenklaus; Véronique Préat; Gaëlle Vandermeulen
Journal:  Mol Ther       Date:  2016-06-20       Impact factor: 11.454

6.  Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.

Authors:  Diletta Di Mitri; Alberto Toso; Jing Jing Chen; Manuela Sarti; Sandra Pinton; Tanja Rezzonico Jost; Rocco D'Antuono; Erica Montani; Ramon Garcia-Escudero; Ilaria Guccini; Sabela Da Silva-Alvarez; Manuel Collado; Mario Eisenberger; Zhe Zhang; Carlo Catapano; Fabio Grassi; Andrea Alimonti
Journal:  Nature       Date:  2014-08-24       Impact factor: 49.962

7.  Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT.

Authors:  Sabrina H L Hoffmann; Andreas Maurer; Dorothea I Reck; Gerald Reischl; Bernd J Pichler; Manfred Kneilling; Christoph M Griessinger
Journal:  J Vis Exp       Date:  2017-04-29       Impact factor: 1.355

Review 8.  Personalized peptide vaccines and their relation to other therapies in urological cancer.

Authors:  Takahiro Kimura; Shin Egawa; Hirotsugu Uemura
Journal:  Nat Rev Urol       Date:  2017-05-31       Impact factor: 14.432

9.  Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells.

Authors:  Caroline Theresa Seebauer; Stefan Brunner; Gabriel Glockzin; Pompiliu Piso; Petra Ruemmele; Hans-Juergen Schlitt; Edward Kenneth Geissler; Stefan Fichtner-Feigl; Rebecca Kesselring
Journal:  Oncoimmunology       Date:  2016-10-14       Impact factor: 8.110

10.  Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease.

Authors:  Neil T Hoa; Lisheng Ge; Rajeev B Tajhya; Christine Beeton; Andrew N Cornforth; Amir Abolhoda; Nils Lambrecht; Maria DaCosta-Iyer; Yi Ouyang; Anthony P Mai; Erin Hong; Judy Shon; Michelle J Hickey; Kate L Erickson; Carol A Kruse; Martin R Jadus
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.